Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Silence Therapeutics ( (SLN) ) just unveiled an announcement.
On June 26, 2025, Silence Therapeutics held its Annual General Meeting where all thirteen proposed resolutions were passed. Key decisions included the reappointment of directors, approval of executive compensation on an annual basis, and the ratification of PricewaterhouseCoopers LLP as auditors. These resolutions reflect the company’s strategic focus on governance and financial oversight, potentially strengthening its operational stability and stakeholder confidence.
The most recent analyst rating on (SLN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.
Spark’s Take on SLN Stock
According to Spark, TipRanks’ AI Analyst, SLN is a Neutral.
Silence Therapeutics is in a growth phase with positive technical momentum, but faces significant financial challenges with negative equity and poor valuation metrics. The stock’s technical strength is its primary asset, though it must address financial and valuation issues for long-term growth.
To see Spark’s full report on SLN stock, click here.
More about Silence Therapeutics
Silence Therapeutics plc operates in the biotechnology industry, focusing on developing RNA-based therapeutics. The company specializes in gene silencing technology, which aims to treat diseases by selectively inhibiting the expression of specific genes.
Average Trading Volume: 211,600
Technical Sentiment Signal: Sell
Current Market Cap: $273.9M
Learn more about SLN stock on TipRanks’ Stock Analysis page.